The study also indicates that the three CSA-signature genes (MYC, MAP2K1, and STAT3) may not only act as potential biomarkers for heart failure but also be potential targets for future research in the development of new treatment strategies for heart failure. The gene discussed is STAT3; the disease is heart failure.